It was noteworthy that the leukemia burden of the combination-treated mice decreased to 2% in PB and 1% in BM (Fig. 5D), which was associated with a markedly higher level of differentiation than that associated with the single-agent treatments, as supported by the upregulation of the differentiation markers CD41, CD42b, and CD61 (Fig. 5E). Here, ITGA2B is linked to leukemia.